HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time
HeartBeam (NASDAQ: BEAT), a medical technology company specializing in cardiac care through personalized insights, has scheduled its Q4 and Full Year 2024 earnings conference call for March 13, 2025, at 4:30 p.m. Eastern time.
The call will feature CEO Robert Eno and CFO Timothy Cruickshank, who will discuss financial results, provide updates on regulatory initiatives, commercial-readiness activities, and anticipated milestones. A detailed press release will be issued before the call, and a presentation will be available during the webcast and afterward through the company's investor relations website.
HeartBeam (NASDAQ: BEAT), un'azienda di tecnologia medica specializzata nella cura cardiaca attraverso intuizioni personalizzate, ha programmato la sua telefonata di conferenza sugli utili del Q4 e dell'intero anno 2024 per il 13 marzo 2025, alle 16:30 ora orientale.
La chiamata vedrà la partecipazione del CEO Robert Eno e del CFO Timothy Cruickshank, che discuteranno i risultati finanziari, forniranno aggiornamenti sulle iniziative regolatorie, sulle attività di preparazione commerciale e sui traguardi previsti. Un comunicato stampa dettagliato sarà emesso prima della chiamata e una presentazione sarà disponibile durante il webcast e successivamente attraverso il sito web delle relazioni con gli investitori dell'azienda.
HeartBeam (NASDAQ: BEAT), una empresa de tecnología médica especializada en el cuidado cardíaco a través de análisis personalizados, ha programado su llamada de conferencia sobre resultados del Q4 y del año completo 2024 para el 13 de marzo de 2025, a las 4:30 p.m. hora del Este.
La llamada contará con la participación del CEO Robert Eno y del CFO Timothy Cruickshank, quienes discutirán los resultados financieros, proporcionarán actualizaciones sobre iniciativas regulatorias, actividades de preparación comercial y hitos anticipados. Se emitirá un comunicado de prensa detallado antes de la llamada, y una presentación estará disponible durante la transmisión en vivo y posteriormente a través del sitio web de relaciones con inversores de la empresa.
HeartBeam (NASDAQ: BEAT), 개인화된 통찰력을 통해 심장 치료를 전문으로 하는 의료 기술 회사가 2024년 4분기 및 연간 실적 컨퍼런스 콜을 2025년 3월 13일 동부 표준시 오후 4시 30분에 예정했습니다.
이번 콜에는 CEO 로버트 에노와 CFO 티모시 크루익샹크가 참석하여 재무 결과를 논의하고, 규제 이니셔티브, 상업 준비 활동 및 예상되는 이정표에 대한 업데이트를 제공할 것입니다. 콜 전에 자세한 보도 자료가 발표될 예정이며, 웹캐스트 중 및 이후 회사의 투자자 관계 웹사이트를 통해 프레젠테이션이 제공될 것입니다.
HeartBeam (NASDAQ: BEAT), une entreprise de technologie médicale spécialisée dans le soin cardiaque grâce à des analyses personnalisées, a programmé sa conférence téléphonique sur les résultats du T4 et de l'année complète 2024 pour le 13 mars 2025 à 16h30, heure de l'Est.
La conférence mettra en vedette le PDG Robert Eno et le CFO Timothy Cruickshank, qui discuteront des résultats financiers, fourniront des mises à jour sur les initiatives réglementaires, les activités de préparation commerciale et les jalons anticipés. Un communiqué de presse détaillé sera publié avant l'appel, et une présentation sera disponible pendant le webinaire et par la suite sur le site des relations investisseurs de l'entreprise.
HeartBeam (NASDAQ: BEAT), ein Medizintechnikunternehmen, das sich auf die kardiologische Versorgung durch personalisierte Einblicke spezialisiert hat, hat seine Q4- und Gesamtjahres 2024 Gewinnkonferenz für den 13. März 2025 um 16:30 Uhr Eastern Time angesetzt.
In dem Call werden CEO Robert Eno und CFO Timothy Cruickshank die Finanzergebnisse besprechen, Updates zu regulatorischen Initiativen, Aktivitäten zur Marktreife und erwarteten Meilensteinen geben. Eine detaillierte Pressemitteilung wird vor dem Call veröffentlicht, und eine Präsentation wird während des Webcasts und anschließend auf der Website der Investor Relations des Unternehmens verfügbar sein.
- None.
- None.
HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here.
To access the call, please use the following information:
Date: |
Thursday, March 13, 2025 |
Time: |
4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
Dial-in: |
1-844-826-3035 |
International Dial-in: |
1-412-317-5195 |
Conference Code: |
10196320 |
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1705718&tp_key=9f12df7745 |
A telephone replay will be available approximately three hours after the call and will run through June 13, 2025, by dialing 1-844-512-2921 from the
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free synthesized 12-lead ECG capable of capturing the heart’s electrical signals from three distinct directions. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227047173/en/
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Source: HeartBeam, Inc.
FAQ
When is HeartBeam's (BEAT) Q4 2024 earnings call scheduled?
Who will be presenting at HeartBeam's (BEAT) upcoming earnings call?
What topics will be covered in HeartBeam's (BEAT) Q4 2024 earnings call?
How long will HeartBeam's (BEAT) Q4 2024 earnings call replay be available?
